This was just a shot in the dark since I read their website and think they are working hard on getting approvals and have success with their compounds.

$AB (+28,65 %) is a clinical-stage pharmaceutical firm developing protein kinase inhibitors, with recent financial data showing a trailing revenue of €1.17 million and a net annual loss of €1.56 million. The company funds R&D primarily through private placements and focuses capital on its masitinib and AB8939 programs.